Scientists Discover Hidden Intracellular Receptor That Ferries Hepatitis B Into the Nucleus
A newly identified protein, SCARF2, acts as an internal escort for HBV, transporting the virus from the cytoplasm to the nuclear pore — a potential new drug target.
Summary
Researchers have identified a second receptor for hepatitis B virus (HBV) that operates inside the cell. After HBV enters liver cells via the known surface receptor NTCP, it still needs to reach the cell nucleus to establish infection. This study reveals that a protein called SCARF2 acts as an intracellular guide, binding to the virus inside endosomes and shepherding it to the nuclear pore complex, where the viral genetic material is released for nuclear entry. Disrupting SCARF2 significantly impairs this process. This discovery fills a major gap in understanding how HBV completes its journey to the nucleus and opens a completely new target for antiviral drug development, potentially complementing existing therapies that block the initial NTCP-mediated entry step.
Detailed Summary
Hepatitis B virus (HBV) chronically infects roughly 300 million people worldwide and remains a leading cause of cirrhosis and liver cancer. Despite decades of research and effective vaccines, a functional cure is elusive. Understanding exactly how HBV hijacks liver cells is essential for developing better treatments.
Researchers at the National Institute of Biological Sciences in Beijing, with collaborators at Harvard Medical School, investigated the poorly understood intracellular phase of HBV infection — what happens after the virus crosses the cell membrane but before it reaches the nucleus. They identified scavenger receptor class F member 2 (SCARF2), a single-pass transmembrane protein, as a critical intracellular receptor for HBV.
The team found that SCARF2 binds to a specific region of the HBV large envelope protein (preS1) that is distinct from the site recognized by the surface receptor NTCP. Binding is mediated through EGF-like domains 4–6 on SCARF2's extracellular N-terminus, while its proline-rich C-terminal domain is also essential for infection. Critically, internalized HBV virions are transported within SCARF2-containing endosomes directly to the cytoplasmic face of nuclear pore complexes. Knocking down SCARF2 impairs nucleocapsid release from endosomes, stalling infection.
These findings propose a two-receptor model: NTCP mediates cell surface attachment and entry, while SCARF2 takes over inside the cell to guide viral cargo to the nucleus. This intracellular handoff represents a previously unrecognized vulnerability in the HBV lifecycle.
For clinicians and researchers, SCARF2 represents a mechanistically distinct drug target that could be exploited alongside or independently of NTCP inhibitors. However, the study has yet to undergo full peer review, and conclusions are drawn from the abstract alone pending access to complete experimental data.
Key Findings
- SCARF2 is identified as an intracellular receptor that binds HBV after cell entry via NTCP.
- SCARF2 binds a distinct preS1 region of HBV's envelope protein through its EGF-like domains 4–6.
- HBV virions travel inside SCARF2-containing endosomes to the surface of nuclear pore complexes.
- Knockdown of SCARF2 impairs nucleocapsid release from endosomes, blocking nuclear entry.
- SCARF2 is a novel, mechanistically distinct antiviral drug target for chronic HBV infection.
Methodology
The study used knockdown experiments, binding assays, and intracellular trafficking analyses to characterize SCARF2's role in HBV infection in hepatocyte models. Structural domain mapping identified the EGF-like domains responsible for preS1 binding. Published as an ahead-of-print article in Cell; full methods are not available from the abstract alone.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; experimental details, sample sizes, and in vivo validation cannot be assessed. The relevance of SCARF2 in primary human hepatocytes and animal models requires confirmation. Patent involvement by lead authors introduces a potential conflict of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.